Finance chief to leave GSK after two transformational deals
The departure provides a further opportunity for GlaxoSmithKline CEO Emma Walmsley to stamp her imprint on Britain’s biggest drug maker
London — GlaxoSmithKline (GSK), Britain’s biggest drug maker, faces more top management change with chief financial officer Simon Dingemans retiring in 2019. The former Goldman Sachs investment banker, who joined in 2011, will step down from the board in May 2019, the company said on Wednesday. As Dingemans’s departure is voluntary he will not receive a severance payment. The group said it planned to look both internally and externally to identify a successor. The departure provides a further opportunity for CEO Emma Walmsley to stamp her imprint on the group as she tries to increase sales and improve productivity in the core pharmaceuticals division. Walmsley, who took over in April 2017, has already appointed a new head of pharmaceuticals in Luke Miels and a new head of drug research in Hal Barron, as well as making Karenann Terrell the head of digital operations, an area within Dingemans’s orbit. In his time at GSK, Dingemans has helped oversee two transformational deals with Nov...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.